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Exercise Training Adds Cardiometabolic Benefits of a Paleolithic Diet
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Background-—The accumulation of myocardial triglycerides and remodeling of the left ventricle are common features in type 2
diabetes mellitus and represent potential risk factors for the development of diastolic and systolic dysfunction. A few studies have
investigated the separate effects of diet and exercise training on cardiac function, but none have investigated myocardial changes
in response to a combined diet and exercise intervention. This 12-week randomized study assessed the effects of a Paleolithic diet,
with and without additional supervised exercise training, on cardiac fat, structure, and function.
Methods and Results-—Twenty-two overweight and obese subjects with type 2 diabetes mellitus were randomized to either a
Paleolithic diet and standard-care exercise recommendations (PD) or to a Paleolithic diet plus supervised exercise training 3 hours
per week (PD-EX). This study includes secondary end points related to cardiac structure and function, ie, myocardial triglycerides
levels, cardiac morphology, and strain were measured using cardiovascular magnetic resonance, including proton spectroscopy, at
baseline and after 12 weeks. Both groups showed major favorable metabolic changes. The PD-EX group showed significant
decreases in myocardial triglycerides levels (45%, P=0.038) and left ventricle mass to end-diastolic volume ratio (13%,
P=0.008) while the left ventricle end-diastolic volume and stroke volume increased significantly (+14%, P=0.004 and +17%,
P=0.008, respectively). These variables were unchanged in the PD group.
Conclusions-—Exercise training plus a Paleolithic diet reduced myocardial triglycerides levels and improved left ventricle
remodeling in overweight/obese subjects with type 2 diabetes mellitus.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01513798. ( J Am Heart Assoc. 2019;8:
e010634. DOI: 10.1161/JAHA.118.010634.)
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I ndividuals with type 2 diabetes mellitus have a 2-foldhigher risk of hospitalization because of heart failure than
those without diabetes mellitus.1 The underlying cause
remains a matter of debate, but 1 possible mechanism is
that the development of structural and functional changes in
the left ventricle (LV) leads to diastolic dysfunction, to
alterations in strain patterns, and later to systolic dysfunction
and clinical signs of heart failure.2,3 These diabetes mellitus–
associated changes, which are not accounted for by hyper-
tension and coronary artery disease, are described as LV
concentric remodeling, which is characterized by an increased
LV mass/LV end-diastolic volume ratio but a normal LV mass
index. The accumulation of myocardial triglycerides (MTGs)
has been suggested to be a possible driver of concentric
remodeling in which an excess of intracellular lipids leads to
hypertrophic signaling.4,5 The use of proton magnetic reso-
nance spectroscopy to noninvasively measure lipid content
revealed an association between MTG levels and concentric
remodeling in both animals and humans.6 In addition, recent
data indicate that the MTG level predicts concentric LV
remodeling in type 2 diabetes mellitus.7
A combination of diet and exercise is a cornerstone of
treatment in type 2 diabetes mellitus,8,9 as it improves
glycemic control, increases insulin sensitivity, reduces fat
mass (including visceral fat), and lowers serum triglycerides.10
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Importantly, the cardiac effects of a combined diet and
exercise intervention in this patient group are unknown.
Weight reduction in obese subjects who have type 2 diabetes
mellitus and who are following a very low-calorie diet
(450 kcal/d) decreases the MTG levels and improves diastolic
LV function.11,12 In contrast, an exercise intervention alone
does not affect MTG levels13,14 but may have beneficial
effects on systolic LV function,13,15 although some earlier
data are not in accordance with this.14
We and others have shown that a Paleolithic-type diet (PD)
may have powerful metabolic effects in type 2 diabetes
mellitus.10,16 Notably, we found previously that there was a
substantial reduction of ectopic fat accumulation in liver in
subjects who were allowed ad libitum intake of this diet,17
which included high intake of vegetables, nuts, fruit, eggs, fish,
and lean meat but excluded dairy products, grains, legumes,
salt, and refined sugar. It is therefore of interest to investigate
the myocardial effects of a PD alone or in combination with
exercise in type 2 diabetes mellitus. Our study included 22
overweight individuals with type 2 diabetes mellitus. We
hypothesized that a 12-week PD intervention would decrease
MTG accumulation and improve cardiac structure and func-
tion. We also hypothesized that additional supervised exercise
training would further improve heart function.
Methods
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Study Design
Overweight and obese individuals with type 2 diabetes
mellitus consumed a PD for 12 weeks and in addition, the
subjects were randomized to standard-care exercise recom-
mendations (PD group) or to receive supervised exercise
training 3 hours per week (PD-EX group). The main results of
the intervention study have been previously published.10 The
outcomes of this article are secondary end points: structural
and functional cardiac measurements using cardiovascular
magnetic resonance (CMR), including proton spectroscopy.
Subjects and Randomization
The dietary and exercise interventions were described in
detail previously.10 Briefly, we recruited patients with type 2
diabetes mellitus by advertising in local newspapers and by
posting flyers at Umea University Hospital. The main inclusion
criteria were age 30 to 70 years, body mass index between
25 and 40 kg/m2, type 2 diabetes mellitus <10 years,
hemoglobin A1c 6.5% to 10.8%, and the use of lifestyle
modification and/or metformin. Only postmenopausal women
were included, a group associated with metabolic distur-
bances and increased risk of cardiovascular complications.
The exclusion criteria were smoking, use of b-blockers, blood
pressure >160/100, known cardiovascular disease, macroal-
buminuria, weight loss (>5% weight loss in the past
6 months), severe illness, and higher level of exercise training
(resistance training once every other week, moderate
endurance training 5 times a week or more).
A total of 261 individuals were interested in participating;
of these 32 (12.3%) participants fulfilled the inclusion criteria
and were randomized into the 2 groups (Figure 1).10 The
participants were assigned to the PD and PD-EX groups using
biased coin minimization with an allocation ratio of 1:1. A
subpopulation of 22 participants underwent complete CMR
analysis, and these 22 comprised the final study population.
The staff who performed the examinations and dietary
counseling was blinded to the allocation. The statistician
who randomized the participants and the research assistant
who informed the participants of their randomization out-
comes were not involved in later data collection or data
analyses. All participants provided written informed consent.
The study protocol fulfilled the tenets of the Helsinki
declaration and was approved by the Regional Ethical Review
Board, Umea, Sweden.
Dietary Intervention
The PD was based on vegetables, fruits, berries, nuts,
seafood, eggs, fish, and lean meat. Dairy products, cereals,
legumes, refined fats, added sugar, and salt were excluded.
Energy intake was ad libitum. Each group participated in 5
Clinical Perspective
What Is New?
• Exercise training in addition to a Paleolithic diet reduced
myocardial triglyceride levels and improved left ventricle
remodeling over a 12-week period in overweight/obese
subjects with type 2 diabetes mellitus.
• Despite causing profound metabolic improvement, the
Paleolithic diet alone had no beneficial effects on cardiac
structure and function.
• No associations were seen between reduction of myocardial
triglyceride levels and changes in cardiac function, arguing
against a simple relationship between these parameters.
What Are the Clinical Implications?
• Exercise training may be an important component to
achieve positive cardiometabolic effects in subjects with
type 2 diabetes mellitus.
• Long-term follow-up including detailed studies of cardiac
metabolism with this type of intervention is of future
interest.
DOI: 10.1161/JAHA.118.010634 Journal of the American Heart Association 2


















 http://ahajournals.org by on O
ctober 6, 2020
group sessions led by a trained dietitian, and the group
members could contact the dietitian between meetings.
Dietary intake was assessed at baseline and at 12 weeks
using self-reported weighed food records.10
Exercise Training Intervention
Before randomization, both intervention groups were advised
to perform at least 30 minutes of moderate exercise daily as
recommended by the current guidelines for patients with type
2 diabetes mellitus. The PD-EX group additionally participated
in a program that combined aerobic and resistance training in
1-hour sessions 3 times a week at the Sports Medicine Unit at
Umea University. The training protocol had a progressive
design in accord with the guidelines of the American College
of Sports Medicine.18 The exercise sessions were performed
on weekdays, with at least 1 day of rest between sessions.
The first session every week consisted of moderate-intensity
aerobic exercise (70% of maximum heart rate) for 20 to
30 minutes on a cross-trainer. The second session of the
week comprised 10 repetitions of 10- to 60-s high-intensity
intermittent training (with 50–90-s of active recovery in
between each repetitions) on a cycle-ergometer; these were
performed at 100% to 110% of the initial VO2max workload.
The third session of the week consisted of 6 moderate-
intensity 5-minute intervals between 45% and 60% of maximal
workload on a cycle-ergometer. All aerobic training sessions
were combined with 30 to 40 minutes of resistance training
that included 10 to 15 repetitions in 2 to 4 sets. These
exercises engaged multiple muscle groups in both the upper
and lower body, including leg curls, leg extensions, leg
presses, hip raises, flat and incline bench presses, seated
rows, dumbbell rows, lat pull-downs, back extensions, shoul-
der raises, burpees, step-ups, wall ball shots, and sit-ups.
Allocated to PD (n=16) 
Received allocated intervention (n=15)
Did not receive allocated intervention, lack of 
 time to participate in diet education (n=1)
Analyzed spectroscopy (n=8) 
Spectroscopy failed (n=4) 
Analyzed CMR (n=12)
CMR discontinued because of 
claustrophobia (n=1)




Spectroscopy failed (n=4) 
Assessed for eligibility (n=261) 
Excluded (n=229)
Not meeting inclusion criteria (n=185)
Declined to participate (n=44) 
Discontinued intervention (n=0) Discontinued intervention (loss of motivation) 
(n=1)
Allocated to intervention (n=16)
Received allocated intervention (n=15)
Did not receive allocated intervention, 








Figure 1. CONSORT flow diagram. CMR indicates cardiovascular magnetic resonance; CONSORT,
Consolidated Standards of Reporting Trials; PD, Paleolithic diet.
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Once participants could manage all repetitions, the workload
was increased for the following session.
Anthropometry and Cardiopulmonary Exercise
Testing
The participants were examined at baseline and after
12 weeks of the intervention at the Clinical Research Center
at Umea University Hospital, Umea, Sweden. Height was
measured using a calibrated height-measuring gauge. Weight
was measured on a calibrated electronic digital scale (Tanita
BWB-800 MA, Umedico AB, Rosersberg, Sweden) with the
participants wearing light clothing. Waist circumference was
assessed between the lowest rib and iliac crest during gentle
exhalation. Systolic and diastolic blood pressure were mea-
sured twice in the right arm with the subject in a sitting
position at 2-minute intervals and once after 5 minutes of rest
using an automated blood pressure meter (Boso Medicus,
Bosch, Germany). Maximal oxygen uptake (VO2 max) and
maximal workload were measured during a cardiopulmonary
exercise test using a Jaeger Oxycon Pro system (Erich Jaeger
GmbH, Hoechberg, Germany) and an 894E Monark cycle
ergometer (Monark, Varberg, Sweden).
Blood Samples
Fasting venous blood samples were analyzed to measure the
serum triglycerides, serum insulin, and hemoglobin A1c at the
Department of Clinical Chemistry, Umea University Hospital.
Fasting glucose was analyzed in a capillary sample (HemoCue
201 RT; Radiometer Medical Aps, Brønshøj, Denmark).
Aliquots of plasma were immediately stored at 80°C.
Nonesterified fatty acids were analyzed with NEFA-HR2
(WAKO Chemicals, Neuss, Germany). Insulin sensitivity was
calculated according to the homeostatic model assessment of
insulin resistance as (fasting glucose9fasting insulin)/22.5.
Cardiovascular Magnetic Resonance
Cardiac structure and function was assessed with a 1.5-T ACS
NT MRI scanner (Philips, Best, The Netherlands). The subjects
lay in a supine position, head first in the bore of the magnet. A
balanced steady-state free precession sequence was used
with ECG-gating and breath holding to measure cardiac
function and morphology. The heart was imaged in short-axis
orientation from the apex to the base with slices. LV end-
systolic volume, end-diastolic volume, and mass were quan-
tified by manually drawing endocardial and epicardial con-
tours (including papillary musculature as part of the LV mass)
in end-diastole and end-systole in short-axis orientation from
the apex to the base. Dedicated software (Segment)19 was
used to assess the LV end-diastolic volume, end-systolic
volume, stroke volume, cardiac output, ejection fraction, and
LV mass. One operator analyzed all CMR scans and was
blinded to treatment assignment and sequence. Intraobserver
variability was assessed using the Bland-Altman method.
Myocardial strain was calculated using 4-chamber and 2-
chamber long-axis views of the ventricle. The LV was
segmented according to the standard 17-segment model.
The apical cap (segment 17) was not considered in the
analysis. Retrospective image analyses were conducted using
2-dimensional CPA CMR Feature tracking software (TomTec
Imaging Systems, Munich, Germany). This tool comprises a
software-based feature-tracking algorithm that has been
validated previously in experimental and clinical studies.20–22
Feature tracking was used to measure the radial and
longitudinal strain along user-defined endocardial and epicar-
dial borders throughout the cardiac cycle on standard CMR
balanced steady-state free precession sequences. In our
study, the strain values were measured by a blinded observer
and were calculated as follows. The peak segmental values of
the longitudinal and transverse strains of the LV derived from
the 4-chamber LAX view were measured, and values were
obtained for the average longitudinal strain, average radial
strain, global longitudinal strain, and global radial strain of the
LV. In addition, we measured the peak segmental values of the
longitudinal and transverse (radial) strains of the LV as derived
from the 2-chamber view.
Spectroscopy
High-resolution cardiac images aligned to 3 orthogonal planes
of the heart were acquired in order to locate the interven-
tricular septum. Images at end-systole were used to position a
spectroscopic sample volume of 10920930 mm3 within the
ventricular septum. During spectroscopic data acquisition,
ECG triggering at end-systole (with the delay from the R-wave
calculated using cine images) and respiratory triggering at
end-exhalation (using a navigator sequence) were performed
simultaneously using the physiological gating capabilities of
the scanner’s spectroscopy package. CMR spectra were
recorded using the PRESS sequence (point-resolved spec-
troscopy) with a repetition time that was typically set to 6
heart beats, giving a repetition time of at least 4 s and an
echo time of 28.7 ms, which was the shortest achievable
echo time. Sixty-four signal averages were acquired from the
spectroscopic volume over 1024 data points covering a 1000-
Hz spectral width. Two spectra were acquired from each
volume, 1 with and 1 without water suppression.
The spectra were analyzed using LCModel software version
6.3–1J (Stephen Provencher, Oakville, Ontario, Canada) using
the built-in model for lipid spectra and using an analysis
window of 3.6 to 1.0 ppm. Signal intensities were extrap-
olated to zero echo time using the assumption that the T2
DOI: 10.1161/JAHA.118.010634 Journal of the American Heart Association 4
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relaxation time of water is 40 ms and the T2 relaxation time
for triglycerides is 78 ms at 1.5 T, while the signal was
acquired at 28.7 ms echo time. The results are reported as
the ratios of the metabolite resonance areas to the unsup-
pressed water resonance. The metabolite resonance that was
used encompassed the sum of the lipid resonances at 1.6,
1.3, and 0.9 ppm. This corresponds well to the “lipid signal”
reported by other groups that used simple integration of the
lipid signals from MR spectra rather than the more sophis-
ticated metabolite models built into LCModel.23
Statistical Analysis
Statistical analyses were performed using SPSS Statistics 23
(IBM Corp, Armonk, NY). The analyses reflect a per-protocol
approach. The null hypothesis was rejected for 2-sided
P<0.05. Because several variables had skewed distribution,
all data were reported as medians with interquartile ranges.
The nonparametric Wilcoxon signed-rank test was used to
compare changes within the groups over time. The Mann–
Whitney U test was used to compare changes between the
intervention groups. In pairwise comparisons, each test was
evaluated separately for missing values. For bivariate corre-
lation analyses, we used a natural logarithm to achieve a
normal distribution of the data.
Results
Patient Characteristics and Cardiometabolic Risk
Markers
The full results from the intervention study regarding compli-
ance with the diet and exercise program, energy balance,
glucose metabolism, cardiovascular fitness, and adipokine
levels were published previously (Table 1).10 In this substudy
group, the PD group had significantly higher diastolic blood
pressure (P=0.03), lower levels of nonesterified fatty acids
(P=0.02), and lower fasting glucose levels (P=0.003) com-
pared with the PD-EX group at baseline. During the interven-
tion, there were significant decreases in both groups in terms
of weight (PD 9% and PD-EX 8%), body mass index (PD
9% and PD-EX 8%), waist circumference (PD 9% and PD-
Table 1. Anthropometric and Metabolic Measurements in Participants During an Intervention With a Paleolithic Diet or a
Paleolithic Diet With Additional Supervised Exercise Training
PD (n=11) PD-EX (n=11)
Group Change
Difference (P Value)Baseline 12 Wks Baseline 12 Wks
Age, y 59 (52–64) 61 (58–66)
Sex, male/female 7/4 7/4
Weight, kg 95 (82–102) 85 (78–97)† 97 (84–116) 90 (76–112)† 0.533
BMI, kg/m2 31 (30–31) 29 (27–30)† 31 (29–37) 29 (27–34)† 0.533
Waist circumference, cm 112 (104–119) 103 (98–109)† 107 (104–116) 99 (94–116)† 0.189
Systolic BP, mm Hg 135 (127–158) 128 (112–128)* 130 (119–138) 119 (112–132)* 0.189
Diastolic BP, mm Hg 87 (84–95) 77 (72–81)† 81 (74–91)‡ 72 (68–81)† 0.305
Heart rate, beats/min 71 (65–80) 72 (61–81) 71 (66–81) 63 (55–75)* 0.056
VO2max, mL/min per kg 22 (21–25) 24 (23–30)
†§ 22 (20–25) 27 (25–30)† 0.005
VO2max total, mL/min 2100 (1900–2600) 2100 (1900–2500)
§ 2200 (1700–2800) 2600 (1800–2900)† 0.048
Maximum workload, Watts 180 (140–200) 180 (170–210)§ 190 (130–240) 220 (150–260)† 0.002
Fasting triglycerides, mmol/L 2.4 (1.2–3.3) 1.2 (0.7–1.9)†§ 1.7 (1.0–2.5) 1.1 (0.9–1.2)† 0.503
Fasting nonesterified fatty acids, mmol/L 0.65 (0.54–0.77) 0.76 (0.49–0.81)k 0.85 (0.66–0.96)‡ 0.77 (0.63–0.91) 0.063
Fasting glucose (HemoCue), mmol/L 7.8 (7.0–8.2) 6.1 (5.5–6.9)*k 10.0 (8.3–12.3)‡ 7.2 (6.4–7.9)† 0.149
HbA1C, mmol/mol 52 (47–56) 42 (41–43)
†§ 57 (51–71) 43 (40–45)* 0.562
Fasting P-insulin, mIU/L 23 (15–28) 12 (9–17)*§ 17 (11–23) 10.0 (8.7–15.0)† 0.648
HOMA-IR 7.0 (5.4–8.6) 3.2 (2.1–5.5)*k 8.1 (6.0–10.2) 3.2 (2.7–4.5)† 0.621
Data are reported as medians (interquartile ranges). BMI indicates body mass index; BP, blood pressure; HbA1c, hemoglobin A1c; HOMA-IR, homeostatic model assessment of insulin
resistance; VO2max, maximal oxygen uptake. The nonparametric Wilcoxon signed-rank test was used to compare values within groups.
*P<0.05, †P<0.01. The Mann–Whitney U test was used to compare changes between the 2 groups.
‡The baseline value differs significantly between groups (P<0.05).
§One missing value in statistical analyses.
kTwo missing values in statistical analyses.
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EX 7%), systolic blood pressure (PD 10% and PD-EX 6%),
diastolic blood pressure (PD 14% and PD-EX 9%), fasting
triglycerides (PD 56% and PD-EX 41%), fasting glucose (PD
17% and PD-EX 26%), hemoglobin A1c (PD 22% and PD-
EX 24%), fasting insulin (PD 38% and PD-EX 39%), and
homeostatic model assessment of insulin resistance (PD
46% and PD-EX 51%). The maximal oxygen uptake
increased significantly in both groups (PD +19% and PD-EX
+19%), although the increase in the PD-EX group was more
pronounced. Mean resting heart rate decreased and the
maximum workload increased significantly in the PD-EX group
(12% and +16%, respectively), while no changes were seen
for these measures in the PD group.
Structural/Functional Cardiac Changes and MTGs
The LV mass, LV end-systolic volume, ejection fraction,
endocardial longitudinal strain, and epicardial longitudinal
strain did not change in either group during the intervention
(Table 2 and Figure 2). Cardiac output decreased significantly
in the PD group (14%) but was unchanged in the PD-EX
group. In the PD-EX group, the stroke volume and LV end-
diastolic volume increased significantly (+17% and +14%,
respectively), and there was a nonsignificant increase in the
global radial strain (+13%, P=0.05). The ratio of the LV mass
to the end-diastolic volume and the MTGs were both
significantly reduced in the PD-EX group (13% and 45%)
but were unchanged in the PD group. Changes over time in
stroke volume, LV end-diastolic volume, and endocardial
global longitudinal strain differed significantly between the
groups (P=0.023, 0.039 and 0.039, respectively), with a
relative increase seen in the PD-EX group.
Bivariate correlation analyses at baseline showed associ-
ations between MTG levels and LVM (P=0.004, r=0.679) and
between MTG levels and cardiac output (P=0.009, r=0.631).
However, no associations were found between changes in the
MTG levels and changes in other functional or structural
cardiac parameters over time (data not shown). There were
associations between changes in the maximal oxygen uptake
(VO2max total) and changes in end-diastolic volume, stroke
volume, and cardiac output (P=0.041, r=0.449; P=0.03,
r=0.474; and P=0.01, r=0.538, respectively). We did not
find any correlations between fasting glucose levels and
functional/structural cardiac parameters at baseline or
between changes in these parameters over time (data not
shown). Furthermore, no associations were found between
weight loss and functional cardiac changes.
Discussion
The main finding of our study was that 12 weeks of a PD plus
exercise training intervention improved several indices of LV
function with a concomitant decrease in MTG levels in
overweight and obese subjects with type 2 diabetes mellitus.
To our knowledge, this is the first study to examine the
detailed cardiac effects of a combined diet and training
intervention in type 2 diabetes mellitus.
Previous investigations of the cardiac effects of lifestyle
interventions in this patient group have focused mainly on
dietary interventions. The PD alone had a powerful impact on
several important metabolic and cardiovascular risk markers
in our study, but there were no specific beneficial effects on
cardiac structure and function. Two previous studies found
reduced MTG levels and improved diastolic function following
a 16-week very low-calorie diet.11,12 This discrepancy could
be explained by the fact that more extreme metabolic
manipulation (ie, 450 kcal/d) is needed to decrease MTG
levels. Another possible explanation is that the macronutrient
composition may have influenced the MTG levels. However, a
study of overweight/obese women reported that moderate
dietary weight loss after reducing carbohydrate or fat intake
also reduced cardiac MTGs, which seems to contradict these
theories.24 Notably, the PD emphasizes increased intake of
mono- and polyunsaturated fatty acids, and this may have
important metabolic effects.25,26
Table 2. Selected Cardiovascular Magnetic Resonance Measurements in Participants During an Intervention With a Paleolithic
Diet or a Paleolithic Diet With Additional Supervised Exercise Training
PD (n=11) PD-EX (n=11)
Group Change
Difference (P Value)Baseline 12 Wks Baseline 12 Wks
LV mass, g 142 (124–179) 140 (124–171) 157 (108–179) 152 (107–177) 0.511
LV end-systolic volume, mL 27 (24–32) 26 (24–34) 34 (24–36) 30 (24–40) 0.743
Ejection fraction, % 74 (71–79) 75 (72–78) 73 (72–77) 76 (73–83) 0.264
Cardiac output, L/min 6.5 (5.8–7.3) 6.0 (5.1–6.8)* 7.3 (5.8–8.8) 6.8 (5.7–8.5) 0.023
Epicardial global longitudinal strain, % 17 (19 to 16) 17 (17 to 15) 18 (19 to 17) 19 (20 to 18) 0.189
Data are reported as medians (interquartile ranges). LV indicates left ventricle. The nonparametric Wilcoxon signed-rank test was used to compare values within groups.
*P<0.05. The Mann–Whitney U test was used to compare changes between the 2 groups.
DOI: 10.1161/JAHA.118.010634 Journal of the American Heart Association 6
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Figure 2. Selected cardiovascular magnetic resonance and spectroscopy findings in participants
during an intervention with a Paleolithic diet (PD) or a Paleolithic diet with additional supervised
exercise training (PD-EX) (A through G). The boxes represent medians and interquartile ranges, and
whiskers represent the range of values, not including the outliers. LVM indicates left ventricle mass;
EDV, end-diastolic volume. The nonparametric Wilcoxon signed-rank test was used to compare
values within the groups. *P<0.05. The Mann–Whitney U test was used to compare changes
between the 2 groups. ‡Significant differences in the changes between the groups (P<0.05).
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The additive effect of exercise training on MTG levels and
heart function was a novel finding in our study. The lower level
of MTGs in the PD-EX group could theoretically improve LV
hemodynamics. However, we did not find any association
between reduced MTG levels and changes in cardiac function,
arguing against a simple relationship between triglyceride
content and cardiac function. This is line with the study by
Jonker et al, who found that the improvement in diastolic
function remained after 14 months of follow-up despite a
return of MTGs to baseline levels.11 Notably, physical activity
energy expenditure (kcal/d and kcal/kg per day) measured
from a combined accelerometer and heart monitor did not
show any significant differences between groups at baseline
or at the 12-week follow-up as reported in a previous
publication.10
The lackof associationsbetweenglucose levels and structural
or functional cardiac parameters partly contrasts with the results
of an earlier study in which fasting blood glucose was identified
as the most important predictor of impairment of cardiac
function in type 2 diabetesmellitus.27 Thismay be relatedmainly
to altered myocardial elastic properties (fibrosis) or to prolonged
ventricular relaxation.27 However, the referenced study showed
associations between glucose levels and diastolic measures
(E/A and diastolic filling rate), parameters not measured in our
study. The change over time in endocardial global longitudinal
strain differed between the PD and the PD-EX groups, suggesting
improved subendocardial function in the PD-EX group.27,28 More
detailed studies on the effect of the PD-EX intervention on
cardiac metabolism, including possible effects on glucose and
fatty acid utilization, are therefore of major interest.29 This
includes studies on the potential reversibility of myocardial
resistance to insulin-mediated glucose uptake, which may
augment fatty acid metabolism.30 In addition, the lower heart
rate, which might be because of altered autonomic balance,
together with the reduction in blood pressure and decreased
blood volume (accompanying weight loss), might have improved
LV performance.
The use of CMR was a major strength of our study, since
this is the criterion standard for obtaining reproducible,
observer-independent measures of LV volume and mass31 and
cardiac strain for detecting subclinical LV dysfunction, which
has important prognostic value.32 The majority of earlier
studies that evaluated LV function and dimensions in subjects
with diabetes mellitus used echocardiography, which has
several limitations, particularly in obese populations. A
limitation of our study was that coronary angiography was
not performed. Therefore, we cannot exclude the possibility
that subclinical coronary artery disease affected myocardial
function in the study subjects. Furthermore, differences
between groups at baseline in some parameters could have
affected the statistical analyses. Hypertension is a common
comorbidity in type 2 diabetes mellitus, which complicates
the assessment of interventions on cardiac function, but
hopefully this affected the 2 groups to a similar extent. The
population size was relatively small, and we did not include a
control group. Furthermore, the optimal time point studying
cardiac effects of different interventions is unknown. We
chose 12 weeks based on previous literature. A long-term
follow-up of the effects of the PD plus exercise training on
MTG levels and cardiac remodeling using this protocol would
be of great interest.
In conclusion, exercise training plus a PD was associated
with beneficial changes in cardiovascular structure and
function in overweight/obese patients with type 2 diabetes
mellitus. The long-term effects of this intervention and the
prognostic value of our findings need to be addressed in
larger prospective studies.
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